INTECH Investment Management’s Protagonist Therapeutics PTGX Stock Holding History

INTECH Investment Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.95M	Buy	24,056 +11,050	+85%	+$1.15M	0.03%	558
2026 Q1	$1.37M	Sell	13,006 -9,479	-42%	-$839K	0.01%	864
2025 Q4	$1.96M	Buy	22,485 +842	+4%	+$68.9K	0.02%	741
2025 Q3	$1.44M	Sell	21,643 -12,310	-36%	-$700K	0.01%	972
2025 Q2	$1.88M	Buy	33,953 +2,971	+10%	+$143K	0.02%	806
2025 Q1	$1.5M	Sell	30,982 -498	-2%	-$20.9K	0.02%	932
2024 Q4	$1.22M	Buy	31,480 +12,352	+65%	+$539K	0.01%	1012
2024 Q3	$861K	Buy	+19,128	New	+$773K	0.01%	899

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

INTECH Investment Management's PTGX Position: Q2 2026 in Review

INTECH Investment Management increased its Protagonist Therapeutics (PTGX) stake by 85% in Q2 2026, buying an estimated $1.15M and bringing the position to 24,056 shares worth $2.95M. The position accounts for 0.03% of the portfolio, ranked #558.

INTECH Investment Management first reported a position in PTGX in Q3 2024 and has held it in 8 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

INTECH Investment Management held 24,056 shares of Protagonist Therapeutics worth $2.95M as of Q2 2026.
INTECH Investment Management bought 11,050 Protagonist Therapeutics shares in Q2 2026, an estimated $1.15M.
Protagonist Therapeutics made up 0.03% of INTECH Investment Management's portfolio in Q2 2026, its #558 holding.
INTECH Investment Management first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 8 quarters since.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.